Financial Synergies Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Financial Synergies Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$414	–	514
2023 Q4	$414	Hold	4	–	–	﹤0.01%	389
2023 Q3	$354	Hold	4	–	–	﹤0.01%	464
2023 Q2	$347	Hold	4	–	–	﹤0.01%	463
2023 Q1	$389	Hold	4	–	–	﹤0.01%	439
2022 Q4	$414	Hold	4	–	–	﹤0.01%	389
2022 Q3	$340	Hold	4	–	–	﹤0.01%	401
2022 Q2	$332	Buy	+4	New	+$318	﹤0.01%	432

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Financial Synergies Wealth Advisors's BMRN Position: Q1 2024 in Review

Financial Synergies Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 4 shares — an estimated $414 sold.

Financial Synergies Wealth Advisors first reported a position in BMRN in Q2 2022 and held it in 7 quarters. The position peaked at $414 in Q4 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Financial Synergies Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Financial Synergies Wealth Advisors sold 4 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $414.
Financial Synergies Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 7 quarters.
Financial Synergies Wealth Advisors's BioMarin Pharmaceuticals position peaked at $414 in Q4 2023.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Financial Synergies Wealth Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.